Amgen has plans to invest in additional manufacturing and R&D operations in the U.S. and will expand its commercial operations in Europe. In Cork, Ireland, the company will invest more than $1 billion in new process development, bulk manufacturing and fill and finish facilities that will give the company capacity closer to the patients it serves in Europe. The company is also adding a manufacturing plant in Puerto Rico to produce Epogen and Aranesp. In 2005, Amgen received licensure of a Neu...